Caroline J. Zinn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline J. Zinn has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- LaTonya J. Hickson
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA
4 shared publications - Lilach O. Lerman
Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
3 shared publications - Anastasia Smith
Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA
2 shared publications - James L. Kirkland
Center for Advanced Gerotherapeutics, Cedars-Sinai Medical Center, Pacific Design Center, West Hollywood, USA
2 shared publications - Joy Wolfram
School of Chemical Engineering The University of Queensland Brisbane Queensland Australia
2 shared publications - Khaled Mosaad Elhusseiny
Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (6)
Platelet-derived purified exosome product (PEP): A clinical-grade lyophilized extracellular vesicle product with broad therapeutic potential, including kidney repair
Extracellular vesicle (EV)-based therapies are rapidly emerging as novel, regenerative cell-free strategies for treating diseases. A current good manufacturing practice (cGMP)-compliant, platelet-derived EV, known as purified exosome product (PEP), has been evaluated in several ongoing preclinical and clinical applications. PEP offers multiple advantages, including abundance and ambient temperature stability. Across 22 published studies, PEP demonstrated pro-angiogenic, anti-inflammatory, and pro-proliferative properties, yielding promising findings in wound, musculoskeletal, cardiovascular, and pulmonary conditions. PEP has been evaluated in phase 2 clinical trials for diabetic foot ulcers and phase 1 clinical trials for various wounds, osteoarthritis, and acute myocardial infarction. However, the therapeutic potential of PEP in kidney disease remains unexplored. Here, we summarize prior and ongoing PEP investigations and introduce PEP reparative effects in a murine model of diabetic kidney disease (DKD), the predominant cause of kidney failure globally. Preliminary findings reveal that intravenous PEP administration reduces kidney fibrosis and hyperglycemia in murine DKD and attenuates fibrogenesis in human proximal tubular cells in vitro. Collectively, PEP demonstrates robust capacity as a regenerative platform with promise to delay disease progression and restore health across multiple organ systems. Further large-scale investigations are warranted to support clinical translation of this promising EV-based technology.
- 1 June 2026
- Published by Tsinghua University Press in Nano Research
- Vol. 19 (6)
Open AccessPlatelet-derived purified exosome product (PEP): A clinical-grade lyophilized extracellular vesicle product with broad therapeutic potential, including kidney repair
Extracellular vesicle (EV)-based therapies are rapidly emerging as novel, regenerative cell-free strategies for treating diseases. A current good manufacturing practice (cGMP)-compliant, platelet-derived EV, known as purified exosome product (PEP), has been evaluated in several ongoing preclinical and clinical applications. PEP offers multiple advantages, including abundance and ambient temperature stability. Across 22 published studies, PEP demonstrated pro-angiogenic, anti-inflammatory, and pro-proliferative properties, yielding promising findings in wound, musculoskeletal, cardiovascular, and pulmonary conditions. PEP has been evaluated in phase 2 clinical trials for diabetic foot ulcers and phase 1 clinical trials for various wounds, osteoarthritis, and acute myocardial infarction. However, the therapeutic potential of PEP in kidney disease remains unexplored. Here, we summarize prior and ongoing PEP investigations and introduce PEP reparative effects in a murine model of diabetic kidney disease (DKD), the predominant cause of kidney failure globally. Preliminary findings reveal that intravenous PEP administration reduces kidney fibrosis and hyperglycemia in murine DKD and attenuates fibrogenesis in human proximal tubular cells in vitro. Collectively, PEP demonstrates robust capacity as a regenerative platform with promise to delay disease progression and restore health across multiple organ systems. Further large-scale investigations are warranted to support clinical translation of this promising EV-based technology.
- Top Cited PapersOpen Access
- 20 January 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106124
Senolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease
- 20 January 2026
- Published by Elsevier in EBioMedicine
- Vol. 124, 106124
Top Cited PapersOpen AccessSenolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease
- 7 May 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1655-1658
Fortifying the Diabetic Kidney Disease Treatment Armamentarium
An abstract is unavailable. This article is available as a PDF only.
- 7 May 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1655-1658
Fortifying the Diabetic Kidney Disease Treatment Armamentarium
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 28 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1278-1291
Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease
Key Points: Activin A is implicated in profibrotic and prosenescent kidney injury and correlates with kidney injury markers in animals and humans. Follistatin, through activin A antagonism, reduces senescence burden, macrophage infiltration, and proinflammatory pathway activation in murine diabetic kidney disease. Follistatin and other antagonists of activin A signaling pathways may be promising, novel therapeutics for diabetic kidney disease. Background: Circulating activin A, an inflammatory mediator implicated in profibrotic kidney injury and cellular senescence-induced adipose tissue dysfunction, is increased in human diabetic kidney disease (DKD) and directly correlates with kidney dysfunction. We tested the hypothesis that activin A increases kidney injury, senescent cell abundance, and macrophage infiltration in DKD and antagonism through follistatin (FS) therapy diminishes these effects. Methods: An accelerated nephropathy type 2 diabetes (db/db) mouse model was generated by implantation of angiotensin II-loaded osmotic minipumps resulting in increased albuminuria and glomerular and tubular injury. Kidney repair effects of FS (5 µg intraperitoneal; two doses) were assessed through markers of kidney injury, fibrosis, inflammation, cellular senescence, and macrophage infiltration. In vitro studies examined antiactivin effects of FS on high glucose-exposed human monocytes, renal fibroblasts, and renal tubule epithelial cells. Results: Activin A antagonism with FS reduced senescence (p19), proinflammatory (including senescence-associated secretory phenotype), and profibrotic markers including activin A. FS improved kidney morphology, restored podocyte markers (nephrin and Wilms tumor-1), and reduced kidney injury biomarkers, albuminuria and kidney fibrosis. FS decreased kidney macrophage and leukocyte infiltration and absent in melanoma 2 inflammasome activation. FS seemed to suppress inflammation through the toll-like receptor-4/NF kappa-light-chain-enhancer of activated B cells pathway in vivo further supported in human macrophages in vitro. In addition, FS reduced hyperglycemia-induced renal fibroblast activation and renal tubule epithelial cell senescence in vitro. Conclusions: Activin A is a mediator of kidney injury through macrophage-associated inflammation in murine DKD. FS acts through senomorphic activities which inhibit profibrotic, proinflammatory, and prosenescence signaling by activin A. Hence, antiactivin targeting may aid in the development of a promising, novel therapeutic for DKD.
- 28 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (8) , 1278-1291
Open AccessActivin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease
Key Points: Activin A is implicated in profibrotic and prosenescent kidney injury and correlates with kidney injury markers in animals and humans. Follistatin, through activin A antagonism, reduces senescence burden, macrophage infiltration, and proinflammatory pathway activation in murine diabetic kidney disease. Follistatin and other antagonists of activin A signaling pathways may be promising, novel therapeutics for diabetic kidney disease. Background: Circulating activin A, an inflammatory mediator implicated in profibrotic kidney injury and cellular senescence-induced adipose tissue dysfunction, is increased in human diabetic kidney disease (DKD) and directly correlates with kidney dysfunction. We tested the hypothesis that activin A increases kidney injury, senescent cell abundance, and macrophage infiltration in DKD and antagonism through follistatin (FS) therapy diminishes these effects. Methods: An accelerated nephropathy type 2 diabetes (db/db) mouse model was generated by implantation of angiotensin II-loaded osmotic minipumps resulting in increased albuminuria and glomerular and tubular injury. Kidney repair effects of FS (5 µg intraperitoneal; two doses) were assessed through markers of kidney injury, fibrosis, inflammation, cellular senescence, and macrophage infiltration. In vitro studies examined antiactivin effects of FS on high glucose-exposed human monocytes, renal fibroblasts, and renal tubule epithelial cells. Results: Activin A antagonism with FS reduced senescence (p19), proinflammatory (including senescence-associated secretory phenotype), and profibrotic markers including activin A. FS improved kidney morphology, restored podocyte markers (nephrin and Wilms tumor-1), and reduced kidney injury biomarkers, albuminuria and kidney fibrosis. FS decreased kidney macrophage and leukocyte infiltration and absent in melanoma 2 inflammasome activation. FS seemed to suppress inflammation through the toll-like receptor-4/NF kappa-light-chain-enhancer of activated B cells pathway in vivo further supported in human macrophages in vitro. In addition, FS reduced hyperglycemia-induced renal fibroblast activation and renal tubule epithelial cell senescence in vitro. Conclusions: Activin A is a mediator of kidney injury through macrophage-associated inflammation in murine DKD. FS acts through senomorphic activities which inhibit profibrotic, proinflammatory, and prosenescence signaling by activin A. Hence, antiactivin targeting may aid in the development of a promising, novel therapeutic for DKD.